BR112022005420A2 - Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina - Google Patents

Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina

Info

Publication number
BR112022005420A2
BR112022005420A2 BR112022005420A BR112022005420A BR112022005420A2 BR 112022005420 A2 BR112022005420 A2 BR 112022005420A2 BR 112022005420 A BR112022005420 A BR 112022005420A BR 112022005420 A BR112022005420 A BR 112022005420A BR 112022005420 A2 BR112022005420 A2 BR 112022005420A2
Authority
BR
Brazil
Prior art keywords
chlorobenzyl
triazol
piperidin
methyl
morpholino
Prior art date
Application number
BR112022005420A
Other languages
English (en)
Inventor
Grzegorz Witkowski
Magdalena Tyszkiewicz
Marcin Zakrzewski
Marta Magdycz
Stanislaw Pikul
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Publication of BR112022005420A2 publication Critical patent/BR112022005420A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina. a presente invenção refere-se a um processo para a síntese de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metilmorfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina em duas formas cristalinas hidratadas e em uma forma cristalina anidrosa. a presente invenção também refere-se a (z)-4-((2s,5s)-5-(4-clorobenzil)-2-metilmorfolino)-n-cianopiperidina-1-carbimidotioato de metila que é um intermediário neste processo.
BR112022005420A 2019-09-25 2020-09-25 Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina BR112022005420A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962905494P 2019-09-25 2019-09-25
PL43126919 2019-09-25
PCT/IB2020/058984 WO2021059220A1 (en) 2019-09-25 2020-09-25 Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine

Publications (1)

Publication Number Publication Date
BR112022005420A2 true BR112022005420A2 (pt) 2022-06-21

Family

ID=73139065

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005420A BR112022005420A2 (pt) 2019-09-25 2020-09-25 Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina

Country Status (13)

Country Link
US (2) US11746107B2 (pt)
EP (1) EP4041726A1 (pt)
JP (1) JP2022549863A (pt)
KR (1) KR20220069008A (pt)
CN (1) CN114466845A (pt)
AU (1) AU2020356534A1 (pt)
BR (1) BR112022005420A2 (pt)
CA (1) CA3155177A1 (pt)
IL (1) IL291569A (pt)
MX (1) MX2022002881A (pt)
TW (2) TWI769532B (pt)
WO (1) WO2021059220A1 (pt)
ZA (1) ZA202204542B (pt)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2802530B1 (fr) * 1999-12-17 2002-02-22 Sanofi Synthelabo Nouveaux derives amino substitues ramifies du 3-amino-1-phenyl-1h[1,2,4]triazole, procedes pour leur preparation et compositions pharmaceutiques les contenant
US7071191B2 (en) * 2000-08-08 2006-07-04 Ortho-Mcneil Pharmaceutical, Inc. Non-imidazole aryloxypiperidines
WO2013178572A1 (en) * 2012-05-30 2013-12-05 F. Hoffmann-La Roche Ag Triazolo compounds as pde10 inhibitors
AU2014369053B2 (en) * 2013-12-20 2019-03-14 Institute For Drug Discovery, Llc Substituted amino triazoles, and methods using same
PL415073A1 (pl) 2014-12-19 2016-06-20 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
GB201513740D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
PL415078A1 (pl) 2015-09-04 2017-03-13 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków
MX2022000306A (es) 2019-07-15 2022-03-11 Oncoarendi Therapeutics Sa Amino triazoles sustituidos utiles como inhibidores de quitinasa.

Also Published As

Publication number Publication date
ZA202204542B (en) 2023-01-25
EP4041726A1 (en) 2022-08-17
TW202126644A (zh) 2021-07-16
CN114466845A (zh) 2022-05-10
KR20220069008A (ko) 2022-05-26
US20240025889A1 (en) 2024-01-25
US11746107B2 (en) 2023-09-05
IL291569A (en) 2022-05-01
TWI769532B (zh) 2022-07-01
US20210147401A1 (en) 2021-05-20
AU2020356534A1 (en) 2022-05-19
WO2021059220A1 (en) 2021-04-01
JP2022549863A (ja) 2022-11-29
MX2022002881A (es) 2022-06-08
CA3155177A1 (en) 2021-04-01
TW202237594A (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
CY1118475T1 (el) Αντιοξειδωτικοι ρυθμιστες φλεγμονης: c-17 ομολογοποιημενα παραγωγα ολεανολικου οξεος
MA49879A (fr) Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CY1116333T1 (el) Παραγωγα βενζοφουρανιου ως ρυθμιστικα μορια των fxr
CO2018005941A2 (es) Formas sólidas de éster etílico del ácido (2r,4s)-5-(bifenil-4-il)-4-[(3-carboxipropionil)amino]-2-metil-pentanoico, sus sales y un método de preparación
PE20171738A1 (es) Proceso para la preparacion de antagonistas del receptor androgeno e intermediarios de los mismos
BR112015019627A2 (pt) amidas heterocíclicas como inibidores de quinases
DOP2013000072A (es) ((r)-(e)-2-(4-(2-(5-(1-(3,5-dicloropiridin-4-il)etoxi)-1h-indazol-3-il)-1h-indazol-3-il)vinil)-1h-pirazol-1-il)etanol cristalino.
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
ECSP11011248A (es) Nuevas formas polimórficas de sal de clorhidrato de 3-(1-{3-[5-(1-metil-piperidin-4-ilmetoxi)-pirimidin-2-il]-bencil}-6-oxo-1,6-dihidro-piridazin-3-il)-benzonitrilo y sus procesos de preparación.
CY1115826T1 (el) Μεσα για τη θεραπεια διαταραχων οι οποιες εμπλεκουν τη ρυθμιση των υποδοχεων ρυανοδινης
UY31004A1 (es) Formas cristalinas de la [3-(4-{ 2-butil-1-[4-(4-cloro-fenoxi)-fenil]-1h-imidazol-4-il}-fenixi)-propil]-dietil-amina
AR111469A1 (es) Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
CY1111701T1 (el) Υδροχλωρικο αλας του 5-[3-(3-υδροξυφαινοξυ)αζετιδιν-1-υλ]-5-μεθυλ-2,2-διφαινυλεξαναμιδιου
CY1124381T1 (el) Παραγωγα οξαδιαζολοπυριδινης για χρηση ως αναστολεις της ο-ακυλο τρανσφερασης της γκρελινης
BR112014032229A2 (pt) método para produção de 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il) piridina-2-carbonitrila, e intermediários da mesma
UY36574A (es) Inhibidores de bromodominios
JOP20200191A1 (ar) مشتقات أوكسادايازولو بيريدين بها استبدال بسيكليل غير متجانسة للاستخدام كمثبطات جريلين o- أسيل ترانسفيراز (goat)
ECSP21067828A (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2-(trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada
NZ595823A (en) 2,5-disubstituted arylsulfonamide ccr3 antagonists
EA201792543A1 (ru) Кристаллическая форма соединения (s)-3-{4-[5-(2-циклопентил-6-метоксипиридин-4-ил)-[1, 2,4]оксадиазол-3-ил]-2-этил-6-метилфенокси}пропан-1,2-диола
BR112022005420A2 (pt) Processo para a produção de 5-(4-((2s,5s)-5-(4-clorobenzil)-2-metil-morfolino)piperidin-1-il)-1h-1,2,4-triazol-3-amina
AR110998A1 (es) Inhibidores de la tirosina cinasa de bruton
CR20160165A (es) Acetato de 4-{4-[(1 e)-4-(2,9- diazaespiro [5.5] undec-2-il) but-1 -en-i -il]-2- metilbencil}-5-(propan-2-il) -1h-pirazol-3-ilo beta-d- glucopiranósido
PH12017500123B1 (en) Crystal of azole benzene derivative
BR112022003171A2 (pt) Processo para a síntese de compostos de pirazolidinona